ClinicalTrials.gg
RecruitingNCT05434130MEDICUpdated Aug 31, 2026

Modulating Exercise Dosage to Improve Concussion Recovery

A Phase 1/2 interventional study of High Dose Exercise in Concussion, Brain, Treatment and Aerobic Exercise, sponsored by University of Colorado, Denver. Recruiting at 3 sites in United States. Open to participants aged 13 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by University of Colorado, Denver · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Study summary

Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity level) initiated within 21 days of concussion results in faster symptom resolution, altered physiological function, or reduced secondary sequalae. Findings from this research will lead to more rigorous and precise rehabilitation guidelines and improved understanding about how exercise affects neurophysiological function among adolescents with concussion.

Read the detailed description

Concussions are defined as a mild form of traumatic brain injury that result in acute neurological dysfunction. Recent work suggests post-concussion aerobic exercise at an intensity level below symptom exacerbation is safe. Yet, clinical benefits from existing randomized controlled trials indicate substantial room for improvement. Also, there is currently an incomplete understanding of the neurophysiology underlying changes in response to exercise treatment. Identifying the precise exercise dose (volume/intensity) required to elicit a therapeutic response following concussion will lead to enhanced and more precise post-concussion rehabilitation strategies. Published and pilot data by the investigators indicate light post-concussion exercise was associated with faster symptom resolution time and less severe symptoms, yet this relied on self-reported data and observational designs. Furthermore, the investigators have identified that the optimal exercise volume to differentiate those with/without concussion symptoms after one month was >160 minutes/week, which is higher than standard exercise volumes prescribed (>100 minutes/week), and in line with existing recommendations for cardiovascular health (>150 minutes/week). Beyond this, given the positive effects of regular moderate exercise to reduce inflammation (e.g., interleukin 6) and restore cerebrovascular regulation, these physiological functions represent viable and feasible rehabilitation targets. Thus, using a prospective randomized clinical trial design, the investigators aim to identify if high dose exercise >(150 minutes/week at an individualized intensity level), relative to standard-of-care, results in: faster/slower symptom resolution, altered physiological function, or reduced secondary sequalae. Our multidisciplinary investigative team has expertise investigating concussion, exercise physiology, fluid biomarkers, cerebrovascular physiology, and psychosocial outcomes. Thus, the investigators will enroll, initially test, and randomize adolescents ages 13-18 years old ≤21 days post-concussion to high dose aerobic exercise or standard-of-care (symptom limited, self-guided physical activity), and reassess upon symptom resolution and 8-weeks post symptom resolution. The investigators will obtain cerebrovascular function and serum biomarker data at each visit, and quantify exercise, symptoms, and secondary sequalae continuously. First, The investigators aim to examine how the dose (intensity, duration, and frequency) of an aerobic exercise program initiated within 21 days of concussion affects time to symptom resolution, relative to standard-of-care, among adolescents. Second, the investigators aim to assess the mechanistic relationship between aerobic exercise, biomarkers of neuroinflammation, and cerebrovascular function. Third, the investigators aim to elucidate how high dose exercise after concussion affects persistent secondary sequalae development (anxiety, depression, kinesiophobia, peer relationships, academic concerns). By challenging the currently accepted, exercise recommendations for sport-related concussion, the investigators will break new ground toward improving rehabilitation strategies.

02

Conditions studied

  • Concussion, Brain
  • Treatment
  • Aerobic Exercise
  • Inflammation
  • Depression, Anxiety

Keywords

  • intervention
  • mild traumatic brain injury
03

In context

Brain Concussion

637 studies on the registry are indexed under Brain Concussion; 163 are open to participants now.

This study's planned enrollment of 178 is above the median of 63 across 446 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

University of Colorado, Denver is the lead sponsor of 1,543 studies on the registry; 317 are open to participants now.

Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 13-18 years of age
  • Post-Concussion Symptom Scale (PCSS) score >10 to ensure participants are not recovered by enrollment
  • Concussion diagnosis by a sports medicine physician

Exclusion criteria

Exclusion Criteria:

  • Pre-existing neurological disorders
  • Exercise
  • Concussion \<6 months before enrollment (excluding the current injury)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
178 participants (estimated)

Study arms

  • Experimental
    High Dose Exercise

    The investigators will provide exercise dose recommendations for initial visit until symptom resolution, and revise upon symptom resolution (to use for the subsequent 8 weeks). These include intensity (target HR) and volume (frequency/duration). Intensity is calculated as 90% of the HR at the end of the exercise test. The volume recommendation is 150 mins/week (\~30 min/day; 5 days/week). The mode of exercise is another consideration. This will be left to participant preference, so that the investigators do not exclude potential participants due to lack of access to specific exercise equipment.

    Behavioral: High Dose Exercise

  • No intervention
    Standard-of-care

    Participants are instructed to perform activity in line with physician recommendations. This consists of a general recommendation (no specific HR/volume) or symptom limited physical activity.

Interventions

  • BehavioralHigh Dose Exercise

    The investigators will initially test and randomize adolescents ages 13-18 years old ≤21 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution

06

What researchers measure

Primary outcomes

  1. Time from injury to symptom resolution

    The PCSS is a standard form that records the presence and severity of 22 concussion symptoms at the time of testing. Participants rate their concussion symptoms from 0-6 where 0 equates to "no symptoms," and 6 to "severe symptoms."

    Time frame: From time of injury until defined symptom resolution observed, about 30 days

  2. Serum biomarker concentration: GFAP change

    Concentrations of GFAP will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  3. Anxiety and depression severity change

    Participants will report anxiety using the Hospital Anxiety and Depression Scale (HADS).The HADS addresses questions related to depression and anxiety symptoms. Responses range from 0 to 3, where 3=experiencing symptoms a great deal of the time, on 14 questions. Seven items are specific to depression symptoms, and 7 to anxiety symptoms. For each sub-scale (HADS-anxiety and HADS-depression) scores range from 0 (no symptoms) to 21 (maximum symptom severity).

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

Secondary outcomes

  1. Serum biomarker concentration: IL-6 change

    Concentrations of IL-6 will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  2. Serum biomarker concentration: TNF-alpha change

    Concentrations of TNF-alpha will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  3. Serum biomarker concentration: IL1-RA change

    Concentrations of IL1-RA will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  4. Serum biomarker concentration: VEGF change

    Serum biomarkers will be obtained via venipuncture at the initial visit, after symptom resolution, and 8 weeks after symptom resolution.

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  5. Serum biomarker concentration: MMP-9 change

    Concentrations of MMP-9 will be simultaneously assayed along with other biomarkers using multi-plex digital array technology, which allows for single molecule immunoarrays while minimizing the amount of sample required

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  6. Cerebral autoregulation

    The investigators will examine the ability to buffer against pressure changes during exercise. Autoregulation will be assessed by deriving the relationship between arterial pressure and cerebral blood flow fluctuations elicited using low resistance breathing.

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  7. Cerebral vasoreactivity change

    The investigators will examine the ability to increase blood flow in response to increases in blood CO2. This is assessed by measuring the progressive increase in cerebral blood flow in response to progressive increases in inspired CO2.

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  8. Kinesiophobia severity change

    The Tampa Scale of Kinesiophobia (TSK) is a 17-item self-report, 4-point Likert scale questionnaire designed to assess fear of pain with movement (kinesiophobia). The questionnaire was originally designed to measure fear of pain during movement among patients with low back pain, and is reliable.

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  9. Peer relationship attitudes change

    Using the Patient Reported Outcomes Measurement Information System (PROMIS), The investigators will obtain data regarding participant attitudes toward peer relationships (friends and other acquaintances).

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

  10. Academic concerns change

    The Concussion Learning Assessment and School Survey (CLASS) aims to assess concern for the effect of concussion on school learning, new or exacerbated post-concussion academic problems, and perceived impact on academic performance.

    Time frame: Baseline, Visit 2 (scheduled after symptoms resolve, about 35 days post-baseline)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Donahue CC, Smulligan KL, Wingerson MJ, Brna ML, Simon SL, Wilson JC, Howell DR. Clinical Cut Point for the Pittsburgh Sleep Quality Index After Adolescent Concussion. Orthop J Sports Med. 2025 Apr 18;13(4):23259671251330571. doi: 10.1177/23259671251330571. eCollection 2025 Apr. PubMed 40297050 ↗
  • Iverson H, Smulligan K, Donahue C, Kniss J, Wingerson M, Wilson J, Howell D. Comparing peer relationship ratings among adolescents with sport and non-sport related concussions. Phys Sportsmed. 2025 Jun;53(3):249-255. doi: 10.1080/00913847.2025.2450216. Epub 2025 Jan 6. PubMed 39760650 ↗
  • Smulligan KL, Armento AM, Brna ML, Meehan WP 3rd, Wilson JC, Howell DR. Low-Energy Availability Indicators Among Female Adolescents After Concussion: A Comparison With Uninjured Controls. Orthop J Sports Med. 2025 Sep 26;13(9):23259671251380877. doi: 10.1177/23259671251380877. eCollection 2025 Sep. PubMed 41019467 ↗
  • Moseley R, Carry PM, Donahue CC, Hicks SD, Simon SL, Wilson J, Meehan WP 3rd, Howell DR. The Dynamic Interaction Between Psychological Health and Sleep Symptoms Following Adolescent Concussion. J Pediatr. 2026 Jan;288:114800. doi: 10.1016/j.jpeds.2025.114800. Epub 2025 Aug 29. PubMed 40887012 ↗
  • Wiegman A, Wingerson M, Smulligan K, Kniss J, Donahue C, Wilson J, Howell D. Clinical predictors of post-concussion kinesiophobia severity among adolescents. Brain Inj. 2026;40(1):1-8. doi: 10.1080/02699052.2025.2565632. Epub 2025 Sep 24. PubMed 40990413 ↗
  • Hurlburt KD, Richardson KL, Wingerson MJ, Kniss JR, Smulligan KL, Wilson JC, Howell DR. NSAID Use Is Not Associated With Persisting Symptoms in Adolescent Concussion. Clin J Sport Med. 2026 Jul 1;36(4):437-443. doi: 10.1097/JSM.0000000000001420. Epub 2026 Feb 2. PubMed 41622533 ↗
  • Donahue CC, Smulligan KL, Wingerson MJ, Kniss JR, Wilson JC, Howell DR. Clinical Cut Point for the Postconcussion Symptom Inventory Following Adolescent Concussion. Med Sci Sports Exerc. 2026 Jun 1;58(6):1140-1148. doi: 10.1249/MSS.0000000000003949. Epub 2026 Jan 26. PubMed 41593831 ↗
  • Salfi ZP, Wingerson MJ, Donahue CC, Smulligan KL, Simon SL, Wilson JC, Howell DR. The Integrated Effect of Physical Activity and Sleep Problems on Concussion Symptom Resolution. J Sport Rehabil. 2026 Apr 9:1-9. doi: 10.1123/jsr.2025-0385. Online ahead of print. PubMed 41956449 ↗
  • Moseley R, Wingerson MJ, Hurlburt KD, Richardson KL, Nagle SM, Wilson JC, Meehan WP 3rd, Howell DR. Concussion Symptom Resolution Expectations and Subsequent Development of Persisting Symptoms After Adolescent Concussion. J Athl Train. 2026 Jun 3;61(6):416-423. doi: 10.4085/1062-6050-0489.25. eCollection 2026 Jun. PubMed 42245142 ↗
  • Moseley RR, Wingerson MJ, Richardson KL, Hurlburt KD, Warren K, Wilson JC, Meehan WP 3rd, Mannix R, Howell DR. Postconcussion physical activity frequency and plasma biomarker associations among adolescents. J Neurosurg Pediatr. 2026 Jun 12:1-8. doi: 10.3171/2026.2.PEDS25624. Online ahead of print. PubMed 42284615 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Feb 2027, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 27, 2022
StartActual
Aug 5, 2022
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05434130
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Aug 5, 2022
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

David R Howell, PhD
Contact
ConcussionResearch@cuanschutz.edu
7207771502
Kelsie Richardson, MS
Contact
ConcussionResearch@cuanschutz.edu
7207771502
David R Howell, PhD
principal investigator · University of Colorado Denver | Anschutz

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion